RPRX Royalty Pharma Plc Class A

Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders

Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders
EN
13/10/2020

Underlying

RPRXRoyalty Pharma Plc Class A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Royalty Pharma Plc Class A

 PRESS RELEASE
Free
RPRX Royalty Pharma ...

Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum

Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the...

September 19, 2025 1 EN
 PRESS RELEASE
Free
RPRX Royalty Pharma ...

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Compa...

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensusGoal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma’s platform valueInvestments since 2020 on track to deliver mid-teens unlevered IRR, ahead of targetAchieved 15% Return on Invested Capital (ROIC) and 21% Return on Invested Equity (ROIE) since 2019Royalty market continues to ...

September 11, 2025 1 EN
 PRESS RELEASE
Free
RPRX Royalty Pharma ...

Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma...

Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma’s diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perception NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, ...

September 10, 2025 1 EN
 PRESS RELEASE
Free
RPRX Royalty Pharma ...

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Hea...

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
RPRX Royalty Pharma ...

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured N...

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 4.450% Notes due 2031 (the “2031 Notes”);$900 million of 5.200% Notes due 2035 (the “2035 Notes”); and$500 million of 5.950% Notes due 2055 (the “2055 Notes”). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, L...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch